A recent article in Science Daily covers research findings by a team at Memorial Sloan-Kettering Cancer Center (MSKCC). The research uncovered a genetic aspect to the spreading of cancer cells long after the treatment for breast cancer. As the author notes, these findings suggest the need for further study and medications that target recurrence and the gene product Src. Read more!
The FDA approved the use of Herceptin® (trastuzumab) as part of a treatment regimen containing doxorubicin, cyclophosphamide and paclitaxel (chemotherapy) for the adjuvant treatment of HER2-postive, node-positive breast cancer on November 16. To read details regarding this action, please click here.
A news story has been released chronicling one man’s fight to bring awareness to inflammatory breast cancer.
Inflammatory Breast Cancer (IBC) is a very aggressive form of breast cancer that can be misdiagnosed.
To watch the news story, click here. For additional information about IBC, visit this website.
Results of a study examining the effectiveness of Raloxifene and Tamoxifen have been released. The article can be found here.
Powered by WordPress